Navigation Links
Phase II Of HDL, Inc. Headquarters Expansion Begins This Week
Date:4/17/2013

RICHMOND, Va., April 17, 2013 /PRNewswire/ -- With its nearly 650 employees moved in and settling into Phase I of its headquarters expansion, Health Diagnostic Laboratory, Inc. started construction this week on Phase II of the 283,000-square-foot complex.

(Photo: http://photos.prnewswire.com/prnh/20130417/PH95656-a )
(Photo: http://photos.prnewswire.com/prnh/20130417/PH95656-b )

Located at the corner of East Jackson and North Fifth streets and bordered to the southeast by Navy Hill Drive, Phase II will be a mirror image of Phase I and connect to it, and when completed in April 2014 will contain 95,000 additional square feet of office and wet laboratory space. One of the nation's fastest-growing companies, HDL, Inc. is a prominent anchor tenant of the Virginia BioTechnology Research Park.

"Our ability to expand so quickly and immensely, from both a real estate and employment perspective, is due to the demand for HDL's advanced testing and health consulting and our ability to deliver high-value services at a low cost to millions of Americans," said Tonya Mallory , HDL, Inc.'s CEO, President and Co-Founder. "It is our mission to prevent and reverse heart disease and related diseases, and this real estate expansion is allowing us to do so as a team in a values-based, innovative environment in downtown Richmond."

Phase I of HDL, Inc.'s expansion was announced in November 2011. Construction required demolition of the former BioTech Three building at the corner of East Jackson and North Fifth streets. Phase I's 112,000-square-foot, six-story complex added to HDL, Inc.'s existing 76,000-square-foot, three-story building – known as BioTech Eight – and construction was completed in February 2013.

At a cos
'/>"/>

SOURCE HDL, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
2. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
3. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. S*BIOs Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF)
6. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
7. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
8. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
9. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
10. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
11. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
(Date:1/14/2014)... 2014 EquitiesIQ, a leading informational research ... Alliqua is an emerging biomedical company acquiring, developing, manufacturing, ... market. , Free report download: http://equitiesiq.com/reports/alliqua/ , ... management team and Board, which launched the company’s new ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... presentation Sunday, May 17, 8:15 a.m. PDT - - ... p.m. PDT - - Conference call and webcast Tuesday, ... 14 InterMune, Inc. (Nasdaq: ITMN ) today ... presentations related to the company,s pulmonology programs will be presented ...
... substantially increased capacity, for continued growth,TORONTO, ... today robust double digit growth in sales, improved cash ... ended March 31, 2009. , In a news release ... 43% growth in the first half of 2009 coupled ...
... Dendreon Corporation today announced that Chief Executive Officer, ... Ernst & Young Entrepreneur Of The Year (R) ... Ernst & Young LLP, the awards program recognizes entrepreneurs ... financial performance and personal commitment to their businesses and ...
Cached Biology Technology:Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 2Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 3Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 4Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 5Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 2Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 3Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 4Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest 2
(Date:7/9/2014)... 2014) Emerging fungal pathogens pose a greater ... causing population declines of amphibians, bats, corals, bees ... South Florida published in the prestigious journal ... or immunological resistance to a deadly chytrid fungus ... "Acquired resistance is important because it is the ...
(Date:7/9/2014)... Cancer Genome Atlas (TCGA) Research Network have identified ... lung adenocarcinoma, the most common subtype of lung ... the number of possible therapeutic targets for this ... patients with treatable mutations because many potent cancer ... TCGA is jointly funded and managed by the ...
(Date:7/9/2014)... shows that some shark species may be able to cope ... with rising temperatures. , The Arctic today is best known ... always like that. Roughly 53 to 38 million years ago ... was more similar to a huge temperate forest with brackish ... of tapirs, hippo-like creatures, crocodiles and giant tortoises. Much of ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... on open water to date and other environmental factors led to ... Mexico, concludes a two-year scientific study released today. A team ... of Central Florida in Orlando published their findings in the journal ... years, scientists have been trying to figure out why there were ...
... PORTLAND, Ore. Researchers at Oregon Health & Science ... protein strongly linked to ALS (Amyotrophic Lateral Sclerosis) and ... different molecular pathways when genetically manipulated. The findings have ... diseases such as Alzheimer,s and Parkinson,s. ...
... For many of us, summer is a time synonymous with ... the United States. In 2011, corn was planted on ... nation continue its trend as the world,s largest exporter of ... desired production levels, most U.S. farmers apply synthetic nitrogen fertilizer ...
Cached Biology News:Study points to causes of high dolphin deaths in Gulf of Mexico 2Scientists develop new carbon accounting method to reduce farmers' use of nitrogen fertilizer 2Scientists develop new carbon accounting method to reduce farmers' use of nitrogen fertilizer 3
... (Ankyrin repeat and SOCS box-containing protein) This ... containing amino acids 75-93 and 348-368 of ... Catalog No. 40149) can be used as ... with mouse and rat Asb-2, based on ...
... Rabbit polyclonal to ErbB 2 - ... for all tested applications). ... AENPEYLGLDVPV conjugated to KLH, corresponding to ... Human c-ErbB2 Entrez ...
SHP-2 Antibody...
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Biology Products: